Cabotegravir And Rilpivirine has 16 known drug interactions based on U.S. FDA drug labeling data. Of these, 1 are contraindicated combinations that should be avoided entirely. Notable interactions include combinations with Cyp3a Inducers, Drugs That Prolong Qtc Interval, Mao Inhibitors. Patients taking Cabotegravir And Rilpivirine should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 16
- Contraindicated
- 1
- Moderate
- 2
Contraindicated (1)
- Cabotegravir And Rilpivirine + Cyp3a Inducers— Strong inducers of UGT1A1 decrease cabotegravir plasma concentrations and may result in loss of virologic response.
Moderate (2)
- Cabotegravir And Rilpivirine + Drugs That Prolong Qtc Interval— CABENUVA should be used with caution in combination with drugs with a known risk of Torsade de Pointes due to rilpivirin…
- Cabotegravir And Rilpivirine + Mao Inhibitors— CYP3A inhibitors may increase rilpivirine plasma concentrations.